New development could increase flu vaccine supply

by Deborah Braconnier report

(Medical Xpress) -- Scientists from the U.S. Food and Drug Administration and the pharmaceutical company Novartis announced today in the journal Science Translational Medicine that they have developed a new adjuvant, or compound that increases the immune response, to add to the current flu vaccines. This adjuvant will allow flu vaccine producers to cut the antigen needed in half and allow for more flu vaccines to be made. This adjuvant would aid in the effectiveness of the flu vaccine while also creating a way to double the U.S. flu vaccine supply.

Adjuvants have already been used for some time in Europe but the U.S. has been slow to adopt them. There is concern that they will receive similar criticism from groups opposed to vaccines as they did when the addition of thimersol, a , was added to the vaccine. While there is already resistance to getting a vaccine, the U.S. didn’t want to add to that possibility.

However, the new adjuvant, known as MF59, is made from squalene, a form of purified shark liver oil. Squalene is naturally produced in the human liver as well. Research has shown that the MF59 vaccine produced a stronger that the current vaccine in use. Squalene has been used in vaccines in Europe since 1997 but this would be the first use of it in a U.S. vaccine.

The vaccine still needs to have the FDA review data and inspect the European production facilities, but it is possible the new vaccine could be available in the fall of 2012.

More information: S. Khurana, N. Verma, J. W. Yewdell, A. K. Hilbert, F. Castellino, M. Lattanzi, G. Del Giudice, R. Rappuoli, H. Golding, MF59 Adjuvant Enhances Diversity and Affinity of Antibody-Mediated Immune Response to Pandemic Influenza Vaccines. Sci. Transl. Med. 3, 85ra48 (2011). DOI: 10.1126/scitranslmed.3002336

ABSTRACT
Oil-in-water adjuvants have been shown to improve immune responses against pandemic influenza vaccines as well as reduce the effective vaccine dose, increasing the number of doses available to meet global vaccine demand. Here, we use genome fragment phage display libraries and surface plasmon resonance to elucidate the effects of MF59 on the quantity, diversity, specificity, and affinity maturation of human antibody responses to the swine-origin H1N1 vaccine in different age groups. In adults and children, MF59 selectively enhanced antibody responses to the hemagglutinin 1 (HA1) globular head relative to the more conserved HA2 domain in terms of increased antibody titers as well as a more diverse antibody epitope repertoire. Antibody affinity, as inferred by greatly diminished (≥10-fold) off-rate constants, was significantly increased in toddlers and children who received the MF59-adjuvanted vaccine. Moreover, MF59 also improved antibody affinity maturation after each sequential vaccination against avian H5N1 in adults. For both pandemic influenza vaccines, there was a close correlation between serum antibody affinity and virus-neutralizing capacity. Thus, MF59 quantitatively and qualitatively enhances functional antibody responses to HA-based vaccines by improving both epitope breadth and binding affinity, demonstrating the added value of such adjuvants for influenza vaccines.

add to favorites email to friend print save as pdf

Related Stories

Vaccines tested for use against bird flu

Mar 31, 2006

Human testing on a two potential vaccines against the H5N1 strain of bird flu has begun in Germany and Belgium, according to GlaxoSmithKline PLC.

WHO approves Glaxo's swine flu shot

Dec 01, 2009

(AP) -- Drug giant GlaxoSmithKline says one of its swine flu vaccines has been certified by the World Health Organization, making it available for donors to buy for developing countries.

Tomato vaccines: New bird flu weapon?

Mar 15, 2006

Australian scientist Amanda Walmsley says she is trying to grow a bird flu vaccine in tomatoes to be used to prevent the disease in chickens.

Recommended for you

Medical charity warns India over patent rules

Jan 21, 2015

Doctors without Borders on Wednesday warned the Indian government not to bow to US pressure to amend patent regulations that allow millions access to affordable medicines, ahead of a visit by President Barack Obama.

Why are some generic drugs getting so expensive?

Jan 21, 2015

More than eight out of every 10 prescriptions dispensed in the US is generic. This growth is due to a large number of top-selling drugs going off patent over the past decade, as well as innovations in t ...

Supreme Court sides with Teva in drug dispute

Jan 20, 2015

The Supreme Court on Tuesday sided with Teva Pharmaceutical Industries Ltd. in the company's high-profile patent dispute with rival firms over the top-selling multiple sclerosis drug.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.